AFP-L3’s specificity for malignant hepatocytes makes it a possible biomarker for distinguishing HCC from cirrhosis, though its sensitivity alone is insufficient for comprehensive screening [47]. The gene discussed is AFP; the disease is hepatocellular carcinoma.